NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of BioAmber Inc. (NYSE: BIOA) resulting from allegations that BioAmber may have issued materially misleading business information to the investing public.
On March 16, 2017, BioAmber during after hours trading announced disappointing financial results for the 2016 fiscal year, missing its previously issued revenue guidance by $1.3 million. On an earnings conference call, President Fabrice Orecchioni of BioAmber, attributed the poor results to “pricing pressures” and “a disruption from a large customer that was expected to purchase 2.8 million of succinic acid in Q4 2016, but due to a technical problem in its manufacturing facility postponed the order to 2017.” On this news, shares of BioAmber fell sharply during intraday trading on March 17, 2017.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by BioAmber investors. If you purchased shares of BioAmber please visit the firm’s website at http://www.rosenlegal.com/cases-1089.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at firstname.lastname@example.org or email@example.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.